<DOC>
	<DOCNO>NCT02295826</DOCNO>
	<brief_summary>Rationale : To date , anticoagulant therapy acute stroke also limit excess hemorrhagic event . The oral anticoagulant dabigatran novel agent , show associate much low intracranial hemorrhage rate . It suggest agent may provide superior benefit anticoagulation acute stroke , without concomitant increase hemorrhage risk associate heparin/LMWH warfarin . Study Design : DATAS II randomize , open label blind endpoint trial . Participants ( n=300 ) TIA ischemic stroke ( NIHSS score &lt; 9 ) enrol within 48 hour symptom onset approximately four ( 4 ) health care centre across Canada . All participant MRI DWI lesion volume &lt; 25 ml . Participants randomize 1:1 treatment dabigatran 30 day ASA 81 mg daily ( current standard care ) . All stroke patient initially screen non-contrast CT scan brain . The first MRI perform within 48 hour symptom onset . Imaging study repeat day 30 . All patient assess clinically Day 30 Day 90 . Study Aims : 1 . Establish safety early anticoagulation novel oral anticoagulant dabigatran acute cerebrovascular syndrome patient . 2 . Identify rate symptomatic asymptomatic hemorrhagic transformation ( HT ) associate treatment . 3 . Identify predictor HT associate acute dabigatran treatment . Hypothesis : The Investigators hypothesize symptomatic HT rate dabigatran ASA treat patient significantly different . Study outcomes : The primary outcome rate symptomatic hemorrhagic transformation ( HT ) , define parenchymal hematoma , &gt; 30 % infarcted area DWI , substantial space- occupy effect , associate clinical worsening ( â‰¥4 point increase National Institutes Health Stroke Scale ( NIHSS ) score ) within 5 week treatment initiation . The major secondary outcome rate asymtomatic HT see day 30 MRI sequence .</brief_summary>
	<brief_title>Dabigatran Following Transient Ischemic Attack Minor Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Ischemic Attack , Transient</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>1 . Male female patient 2 . Must &gt; 18 year age 3 . Must TIA ischemic stroke ( NIHSS score &lt; 9 see section 2.7 clarification ) 4 . Symptom onset &lt; 48 hour prior enrollment Study therapy must initiate within 48 hour symptom onset ( case onset time establish , consider time patient lst know well 5 . Informed consent must obtain either patient substitute decision maker ( accord local REB policy ) prior study related procedure perform 6 . All patient MRI include DWI prior randomization 7 . DWI lesion volume must &lt; 25ml 8 . Patients without DWI lesion , clinical history consider consistent TIA , determine attend physician , include 1 . Patients stroke mimic seizure , migraine etc 2 . Patients contraindication MRI include metallic implant 3 . Patients past sensitivity gadolinium contrast medium eligible , undergo PWI contrast enhance MRA ( optional sequence ) 4 . Patients renal failure define Glomerular Filtration Rate ( GFR ) &lt; 30 ml/min 5 . Patients deem , attend stroke physician , ongoing bleed risk unsuitable dabigatran therapy 6 . Patients MRI demonstrate additional pathology include arteriovenous malformation , intracranial aneurysm , tumor abscess , potentially increase rise bleed . Individuals small incidental leasions , low risk bleed meningioma may include discretion investigator . 7 . Patients acute DWI lesion volume &gt; 25 ml ( DWI volume estimate use ABC/2 technique 110 ) ** 8 . Age &lt; 18 year 9 . Pregnant breast feed woman . 10 . Severe dysphagia necessitate nasogastric ( NG ) feeding ( dabigatran deliver via NG tube ) 11 . Planned thrombolysis endovascular intervention index event 12 . Thrombolysis ischemic stroke within precede 7 day 13 . Planned carotid endarterectomy/carotid artery stent within 30 day Note : Carotid Investigations complete prior enrolment . Patients symptomatic stenosis plan carotid procedure exclude . 14 . Any history spontaneous intracranial bleeding 15 . Clear indication anticoagulation , include atrial fibrillation , mechanical cardiac valve , deep venous thrombosis , pulmonary embolism know hypercoagulable state 16 . Comorbid illness expect life expectancy &lt; 90 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>